EFPIA recommends wider adverse reaction reporting in EU assessments

Published: 17-Oct-2014
Regulatory

Voices concerns that proposed rules would not give pharma companies sufficient flexibility


The European Federation of Pharmaceutical Industries & Associations (EFPIA) has recommended changes to new draft guidance prepared by the European Medicines Agency (EMA) on reporting adverse reactions during medicine assessments.

The EFPIA is concerned that the current proposed rules would not give pharma companies sufficient flexibility to report adverse reactions that were beyond the formal focus of a medicine safety study.

In a public consultation staged by the EMA, the EFPIA noted that 'over-reporting of adverse events by investigators is common in non-interventional studies', with pharmaceutical companies receiving valid individual case safety reports (ICSRs) from investigators 'that should not have been forwarded according to the study protocol'.

The EFPIA argued that under EMA’s proposed wording, such valid ICSRs would not be reported. It has proposed changes to the guidance that would 'allow this flexibility', and which would 'would greatly reduce administrative burden for companies'. However, such problems 'should only be summarised in the interim or final study report'.

  • Companies:
  • EFPIA
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Laying a new path for orphan drugs

Read more
Important changes in the way that the EU deals with orphan medicines could be signalled later this year when the European Commission publishes a revised version of its 2003 Communication (policy paper) on the topic

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Laying a new path for orphan drugs

Important changes in the way that the EU deals with orphan medicines could be signalled later this year when the European Commission publishes a revised version of its 2003 Communication (policy paper) on the topic
Regulatory

EU pharma associations seek orphan drug reform

One key issue is the need to demonstrate that an orphan medicine has a significant benefit over existing treatments
Regulatory

EFPIA says dedicated facilities not needed if EMA cross-contamination guidance works

Comments on a draft European Medicines Agency (EMA) guideline on setting health-based exposure limits for assessing the risk of manufacturing different medicinal products in shared facilities
Regulatory

Pharma associations take action over national European off-label authorisation laws

They could be a disincentive to pharma companies developing drugs for rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

EU celebrates 50 years of pharmaceutical legislation

<i>Manufacturing Chemist</i> asked public health organisations, industry and the academic community for their views on half a century of EU pharmaceutical legislation. The responses suggest that some organisations believe that it is far from perfect
Regulatory

European industry associations seek international co-ordination on cocrystal regulation

Salts and cocrystals can equally be accepted as drug substances
Regulatory

EFPIA calls for more flexibility in EU GMP advice on qualification and validation

There could be more need in future to concurrently 'validate' products earlier in the lifecycle
Subscribe now